These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29860358)

  • 1. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
    Morano F; Corallo S; Niger M; Barault L; Milione M; Berenato R; Moretto R; Randon G; Antista M; Belfiore A; Raimondi A; Nichetti F; Martinetti A; Battaglia L; Perrone F; Pruneri G; Falcone A; Di Bartolomeo M; de Braud F; Di Nicolantonio F; Cremolini C; Pietrantonio F
    Ann Oncol; 2018 Aug; 29(8):1800-1806. PubMed ID: 29860358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
    Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Pietrantonio F; Lobefaro R; Antista M; Lonardi S; Raimondi A; Morano F; Mosconi S; Rimassa L; Murgioni S; Sartore-Bianchi A; Tomasello G; Longarini R; Farina G; Petrelli F; Gori S; Randon G; Corallo S; Pagani F; Guarini V; Palermo F; Martinetti A; Macagno M; Barault L; Perrone F; Tamborini E; Milione M; Di Nicolantonio F; Di Maio M; Fucà G; Di Bartolomeo M; de Braud F
    Clin Cancer Res; 2020 Mar; 26(5):1017-1024. PubMed ID: 31740551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
    Amatu A; Barault L; Moutinho C; Cassingena A; Bencardino K; Ghezzi S; Palmeri L; Bonazzina E; Tosi F; Ricotta R; Cipani T; Crivori P; Gatto R; Chirico G; Marrapese G; Truini M; Bardelli A; Esteller M; Di Nicolantonio F; Sartore-Bianchi A; Siena S
    Ann Oncol; 2016 Jun; 27(6):1062-1067. PubMed ID: 26916096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
    Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
    Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
    Pietrantonio F; Perrone F; de Braud F; Castano A; Maggi C; Bossi I; Gevorgyan A; Biondani P; Pacifici M; Busico A; Gariboldi M; Festinese F; Tamborini E; Di Bartolomeo M
    Ann Oncol; 2014 Feb; 25(2):404-8. PubMed ID: 24379162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    Calegari MA; Inno A; Monterisi S; Orlandi A; Santini D; Basso M; Cassano A; Martini M; Cenci T; de Pascalis I; Camarda F; Barbaro B; Larocca LM; Gori S; Tonini G; Barone C
    Br J Cancer; 2017 May; 116(10):1279-1286. PubMed ID: 28427088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
    Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Sartore-Bianchi A; Pietrantonio F; Amatu A; Milione M; Cassingena A; Ghezzi S; Caporale M; Berenato R; Falcomatà C; Pellegrinelli A; Bardelli A; Nichelatti M; Tosi F; De Braud F; Di Nicolantonio F; Barault L; Siena S
    Eur J Cancer; 2017 Jan; 71():43-50. PubMed ID: 27997874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemoradiotherapy with temozolomide, vincristine, and interferon-β might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma.
    Asano K; Fumoto T; Matsuzaka M; Hasegawa S; Suzuki N; Akasaka K; Katayama K; Kamataki A; Kurose A; Ohkuma H
    BMC Cancer; 2021 Jul; 21(1):867. PubMed ID: 34320929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
    Amatu A; Sartore-Bianchi A; Moutinho C; Belotti A; Bencardino K; Chirico G; Cassingena A; Rusconi F; Esposito A; Nichelatti M; Esteller M; Siena S
    Clin Cancer Res; 2013 Apr; 19(8):2265-72. PubMed ID: 23422094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
    Hassel JC; Sucker A; Edler L; Kurzen H; Moll I; Stresemann C; Spieth K; Mauch C; Rass K; Dummer R; Schadendorf D
    Br J Cancer; 2010 Sep; 103(6):820-6. PubMed ID: 20736948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
    Schäfer N; Proescholdt M; Steinbach JP; Weyerbrock A; Hau P; Grauer O; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Grau S; Hänel M; Schnell O; Krex D; Vajkoczy P; Tabatabai G; Mack F; Schaub C; Tzaridis T; Nießen M; Kebir S; Leutgeb B; Urbach H; Belka C; Stummer W; Glas M; Herrlinger U
    Neuro Oncol; 2018 Jun; 20(7):975-985. PubMed ID: 29121274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
    Sardi I; Cetica V; Massimino M; Buccoliero AM; Giunti L; Genitori L; Aricò M
    Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.